Eli Lilly’s migraine treatment was approved by the US FDA, closely following a positive CHMP opinion, and will potentially be made available without cost for the first year.
Regulatory setbacks at Teva’s CMO facility in Korea have not halted the regulatory progression of preventive migraine treatment Ajovy, which has received US FDA approval.
Avanir Pharmaceuticals has bought North American rights to OptiNose’s novel intranasal delivery system to treat acute migraines, which is expected to be filed for US FDA approval by early 2014.
